Rezolute (RZLT) Capital Expenditures (2013 - 2022)

Rezolute (RZLT) posted Capital Expenditures of $83000.0 for Q4 2022, up 18.57% sequentially from $70000.0 in Q3 2022.

Rezolute (RZLT) Capital Expenditures (2013 - 2022) Analysis & Trends

Rezolute has reported Capital Expenditures for 8 years, with the latest figure at $83000.0 in Q4 2022.

Quarterly Capital Expenditures changed N/A year-over-year to $83000.0 in Q4 2022, while the trailing twelve-month figure through Jun 2023 was $153000.0 (changed N/A YoY) and the FY2023 annual result came in at $153000.0, changed N/A from the prior year.
Capital Expenditures advanced to $83000.0 in Q4 2022 per RZLT's latest filing, from $70000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $83000.0 in Q4 2022 and troughed at $184.0 in Q2 2018.
A 3-year average of $40036.8 and a median of $41000.0 in 2019 frame the typical range for Capital Expenditures.
The sharpest annual moves came in 2018 and 2019: Capital Expenditures slumped 99.83% in 2018, then surged 3160.87% in 2019.
Over 3 years, Capital Expenditures stood at $184.0 in 2018, then soared by 3160.87% to $6000.0 in 2019, then soared by 1283.33% to $83000.0 in 2022.
According to Business Quant data, Capital Expenditures over the past three periods registered $83000.0, $70000.0, and $6000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Rezolute	442.94 Mn	442.94 Mn	-	-

Download Data